{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Roeker LE"],"funding":["NCI NIH HHS","national cancer institute"],"pagination":["133-143"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9521791"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["82(2)"],"pubmed_abstract":["In this review, we examine the literature supporting treatment decision making in the front-line and relapsed/refractory settings for patients with chronic lymphocytic leukemia (CLL). In the front-line setting, novel-agent-based approaches, including continuous Bruton tyrosine kinase (BTK) inhibitor-based therapy and time-limited venetoclax with obinutuzumab, have demonstrated survival benefit over chemoimmunotherapy. While novel-agent-based front-line approaches are appropriate for most patients, fludarabine, cyclophosphamide, and rituximab (FCR) remains a consideration for a selected population of young patients with immunoglobulin heavy chain variable region gene (IGHV)-mutated disease because of the possibility of a prolonged remission following FCR. As front-line novel-agent-based app"],"journal":["Drugs"],"pubmed_title":["Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy."],"pmcid":["PMC9521791"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Roeker LE","Thompson M","Mato AR"],"additional_accession":[]},"is_claimable":false,"name":"Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.","description":"In this review, we examine the literature supporting treatment decision making in the front-line and relapsed/refractory settings for patients with chronic lymphocytic leukemia (CLL). In the front-line setting, novel-agent-based approaches, including continuous Bruton tyrosine kinase (BTK) inhibitor-based therapy and time-limited venetoclax with obinutuzumab, have demonstrated survival benefit over chemoimmunotherapy. While novel-agent-based front-line approaches are appropriate for most patients, fludarabine, cyclophosphamide, and rituximab (FCR) remains a consideration for a selected population of young patients with immunoglobulin heavy chain variable region gene (IGHV)-mutated disease because of the possibility of a prolonged remission following FCR. As front-line novel-agent-based app","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-19T14:19:53.699Z","creation":"2025-02-19T04:46:04.945Z"},"accession":"S-EPMC9521791","cross_references":{"pubmed":["34932207"],"doi":["10.1007/s40265-021-01657-0"]}}